Key facts
- Bioptimus’s last known valuation is $159.5M (Jan 2025).
- It has raised $76.4M; the latest was Accelerator/Incubator in Jun 2025.
- Notable investors include Bpifrance, La French Tech, Headline, Sofinnova Partners, Cathay Innovation — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Bioptimus
- ·The full record, as it builds
Funding rounds
No funding rounds for Bioptimus are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bioptimus
Developer of a universal artificial intelligence foundation model designed to drive scientific research and biotechnological innovation. The company's model connects the different scales of biology with generative artificial intelligence, from molecules to cells, tissues, and whole organisms, enabling researchers to transform multiscale data into actionable representations to fuel discoveries.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2023
- Employees
- 1
- Website
- bioptimus.com/
- Ownership
- Privately Held (backing)
Bioptimus doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bioptimus shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bioptimus in its N-PORT filings yet. We sweep new filings monthly.